IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, C
Go back to IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, C| (NASDAQ: IDYA) | Delayed: 28.98 +0.14 (0.49%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.84 | 52 Week High | $ | |||
| Open | $29.01 | 52 Week Low | $ | |||
| Day High | $29.76 | P/E | N/A | |||
| Day Low | $28.90 | EPS | $ | |||
| Volume | 617,365 | |||||
